| First-in-human experience of CXCR4-directed endoradiotherapy with 177Lu-and 90Y-labeled pentixather in advanced-stage multiple myeloma with extensive intra-and extramedullary … K Herrmann, M Schottelius, C Lapa, T Osl, A Poschenrieder, H Hänscheid, ... Journal of nuclear medicine 57 (2), 248-251, 2016 | 262 | 2016 |
| In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma K Philipp‐Abbrederis, K Herrmann, S Knop, M Schottelius, M Eiber, ... EMBO molecular medicine 7 (4), 477-487, 2015 | 219 | 2015 |
| [68Ga] Pentixafor-PET/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma-Comparison to [18F] FDG and laboratory values C Lapa, M Schreder, A Schirbel, S Samnick, KM Kortüm, K Herrmann, ... Theranostics 7 (1), 205, 2017 | 215 | 2017 |
| The Fas ligand intracellular domain is released by ADAM10 and SPPL2a cleavage in T-cells V Kirkin, N Cahuzac, F Guardiola-Serrano, S Huault, K Lückerath, ... Cell Death & Differentiation 14 (9), 1678-1687, 2007 | 177 | 2007 |
| CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed multiple myeloma C Lapa, K Herrmann, A Schirbel, H Hänscheid, K Lückerath, ... Theranostics 7 (6), 1589, 2017 | 129 | 2017 |
| 68Ga-pentixafor-PET/CT for imaging of chemokine receptor 4 expression in glioblastoma C Lapa, K Lückerath, I Kleinlein, CM Monoranu, T Linsenmann, ... Theranostics 6 (3), 428, 2016 | 109 | 2016 |
| Investigating PSMA-targeted radioligand therapy efficacy as a function of cellular PSMA levels and intratumoral PSMA heterogeneity K Current, C Meyer, CE Magyar, CE Mona, J Almajano, R Slavik, ... Clinical Cancer Research 26 (12), 2946-2955, 2020 | 102 | 2020 |
| [68Ga] Pentixafor-PET/CT for imaging of chemokine receptor 4 expression in small cell lung cancer-initial experience C Lapa, K Lückerath, M Rudelius, JS Schmid, A Schoene, A Schirbel, ... Oncotarget 7 (8), 9288, 2016 | 100 | 2016 |
| Correlation of 68Ga-FAPi-46 PET biodistribution with FAP expression by immunohistochemistry in patients with solid cancers: interim analysis of a prospective translational … CE Mona, MR Benz, F Hikmat, TR Grogan, K Lueckerath, A Razmaria, ... Journal of Nuclear Medicine 63 (7), 1021-1026, 2022 | 96 | 2022 |
| 11C-methionine-PET in multiple myeloma: correlation with clinical parameters and bone marrow involvement C Lapa, S Knop, M Schreder, M Rudelius, M Knott, G Jörg, S Samnick, ... Theranostics 6 (2), 254, 2016 | 89 | 2016 |
| Pitfalls and common findings in 68Ga-FAPI PET: a pictorial analysis L Kessler, J Ferdinandus, N Hirmas, F Zarrad, M Nader, D Kersting, ... Journal of Nuclear Medicine 63 (6), 890-896, 2022 | 77 | 2022 |
| 11C-methionine-PET in multiple myeloma: a combined study from two different institutions C Lapa, MJ Garcia-Velloso, K Lückerath, S Samnick, M Schreder, ... Theranostics 7 (11), 2956, 2017 | 76 | 2017 |
| Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities WP Fendler, KM Pabst, L Kessler, P Fragoso Costa, J Ferdinandus, ... Clinical Cancer Research 28 (19), 4346-4353, 2022 | 72 | 2022 |
| Immune-checkpoint blockade enhances 225Ac-PSMA617 efficacy in a mouse model of prostate cancer J Czernin, K Current, CE Mona, L Nyiranshuti, F Hikmat, CG Radu, ... Journal of Nuclear Medicine 62 (2), 228-231, 2021 | 72 | 2021 |
| Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer K Lückerath, L Wei, WP Fendler, S Evans-Axelsson, AD Stuparu, R Slavik, ... EJNMMI research 8, 1-9, 2018 | 71 | 2018 |
| 18FDG-PET/CT for prognostic stratification of patients with multiple myeloma relapse after stem cell transplantation C Lapa, K Lückerath, U Malzahn, S Samnick, H Einsele, AK Buck, ... Oncotarget 5 (17), 7381, 2014 | 70 | 2014 |
| Runx2 is expressed in human glioma cells and mediates the expression of galectin‐3 V Vladimirova, A Waha, K Lückerath, P Pesheva, R Probstmeier Journal of neuroscience research 86 (11), 2450-2461, 2008 | 69 | 2008 |
| Palmitoylation of human FasL modulates its cell death-inducing function F Guardiola-Serrano, A Rossin, N Cahuzac, K Lückerath, I Melzer, ... Cell death & disease 1 (10), e88-e88, 2010 | 58 | 2010 |
| Somatostatin receptor expression in small cell lung cancer as a prognostic marker and a target for peptide receptor radionuclide therapy C Lapa, H Hänscheid, V Wild, T Pelzer, A Schirbel, RA Werner, S Droll, ... Oncotarget 7 (15), 20033, 2016 | 57 | 2016 |
| Chemokine receptor–directed imaging and therapy AK Buck, A Stolzenburg, H Hänscheid, A Schirbel, K Lückerath, ... Methods 130, 63-71, 2017 | 54 | 2017 |
